

### Remarks

Applicants gratefully acknowledge the Examiner's allowance of claims 1, 2, 7, 10, 11, 20, and 21. Claim 22 has been canceled.

Applicants respectfully request reconsideration of the Examiner's rejection of claims 3, 4, and 9 under 35 U.S.C. 102(b) in view of the foregoing amendments. Claim 3 now depends from claim 7, which has been indicated to be allowable by the Examiner. Claims 4 and 9 both depend from claim 3. Accordingly, it is respectfully submitted that the ground for the rejection of claims 3, 4, and 9 have been overcome by the present amendment, and that the claims are in condition for allowance. Such action is earnestly solicited.

Respectfully submitted,



David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6946

Date: January 3, 2003

**Version of Claims with Markings to Show Changes Made**

3. (Four Times Amended) A vector molecule comprising [a member selected from the group consisting of a polynucleotide comprising at least 297 contiguous nucleotides of coding sequence from SEQ ID NO:1 and an isolated DNA according to claim 1] an isolated DNA according to claim 7.